comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 12:21:52 - browse：71

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Having children helps parents live longer, especially after age 80

hotspot

explore

WSS

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Lawmakers grill UnitedHealth CEO on Change cyberattack

Deliver public health messages at the right time

Can gargling with Listerine treat gonorrhea of the mouth?

Brain MRIs reveal impact of 'toxic stress' on Black children

hotspot

comprehensive

focus

Peter Hotez and the public health issue of online harassment

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

AI for drug discovery: Experts on separating hype from reality

Hepatitis C has a cure — but many Americans still lack access to it

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Duchenne breakthrough therapy leaves behind pioneering families

Congress must protect the remaining independent doctors

Bright Health sells Medicare Advantage business to Molina

Report cites 'urgent' need to recruit more diverse clinical trial participants

entertainment

Congress might make insulin pumps more accessible to the blind

Ebola vaccine can save some who are already sick, per new study

Tome Biosciences co

Too many hospitalized Covid

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Having children helps parents live longer, especially after age 80

entertainment

hotspot

explore

entertainment